Cash-strapped gene-therapy company Bluebird bio agreed to be acquired by private-equity firms Carlyle Group and SK Capital ...

Bluebird Bio has commercialized three gene therapy products, including one of the first for sickle cell disease, but would soon run out of cash.

A pair of investors will acquire bluebird bio in a deal worth only $29 million upfront after the gene therapy maker ran out ...

The Carlyle Group and SK Capital Partners have agreed to acquire bluebird bio, Inc, a Somerville, Massachusetts-based gene therapy firm, in a take-private deal. According to terms of the agreement, ...

Gene therapy developer bluebird bio (NASDAQ:BLUE) announced Friday its plans to become a privately held biotech as part of an M&A agreement with private equity firms, Carlyle Group (NASDAQ:CG) and SK ...

The agreement, which also includes a team of biotech executives, will see Bluebird Bio’s stockholders receive $3.00 per share ...

Birds-of-paradise are even colorful in the dark, with feathers and body parts that glow a brilliant yellow-green under ...

Third-year trainer Rory Hunter has already achieved his dream of having a Blue Diamond runner with a horse he thought would ...

The global citizen science project, which runs through Monday, allows scientists to collect data on wild birds, helping to ...

Study finds that birds-of-paradise are biofluorescent, suggesting that this "hidden" phenomenon provides enhanced signaling for hierarchy and courtship.

Columnist Bill Danielson explores the challenge of identifying individual birds and the rare moments that make one stand out ...